#1 Clinical Trials Search in Europe

Medroxyprogesterone Acetate

Medroxyprogesterone Acetate, commonly known as Depo-Provera, is a hormonal medication used primarily for contraception. This article explores various clinical trials investigating the use of this drug for birth control and other medical purposes. We’ll look at studies examining different administration methods, timing, and potential effects on breastfeeding and postpartum depression.

Table of Contents

What is Medroxyprogesterone Acetate?

Medroxyprogesterone Acetate (MPA) is a synthetic form of the hormone progesterone. It is commonly known by brand names such as Depo-Provera, depo-subQ 104, Provera, and Cycrin[1][2]. This medication is used for various medical purposes, primarily in women’s health.

Uses of Medroxyprogesterone Acetate

Medroxyprogesterone Acetate has several medical applications:

  • Contraception: It is widely used as a long-acting reversible contraceptive[1].
  • Treatment of abnormal uterine bleeding: MPA can help manage conditions like dysfunctional uterine bleeding[5].
  • Hormone replacement therapy: It’s used in postmenopausal women for hormone replacement[2].
  • Potential benefits in sickle cell disease: Research is being conducted on its effects in reducing pain for women with sickle cell disease[7].

How is Medroxyprogesterone Acetate Administered?

Medroxyprogesterone Acetate can be administered in several ways:

  • Intramuscular injection: The most common form for contraception, typically given every 3 months (13 weeks) at a dose of 150 mg[1].
  • Subcutaneous injection: A newer formulation that can be self-administered[3].
  • Oral tablets: Used for various conditions, including abnormal uterine bleeding[5].
  • Vaginal ring: Some studies have explored the use of MPA in vaginal ring form[4].

Medroxyprogesterone Acetate for Contraception

As a contraceptive, Medroxyprogesterone Acetate (often referred to as DMPA or Depo-Provera) is highly effective. It works by preventing ovulation, thickening cervical mucus, and thinning the lining of the uterus[1]. Some key points about its use as a contraceptive include:

  • It is typically administered every 3 months (13 weeks).
  • It can be given as an intramuscular or subcutaneous injection.
  • Some women may be able to self-administer the subcutaneous form at home[1].
  • It is a reversible form of contraception, meaning fertility can return after stopping use.

Treatment of Bleeding Disorders

Medroxyprogesterone Acetate has shown effectiveness in treating abnormal uterine bleeding, also known as dysfunctional uterine bleeding. In one study, researchers used a combination of high-dose oral MPA tablets and an injection of DMPA to treat acute heavy, prolonged uterine bleeding in an outpatient setting[5]. This treatment approach aimed to quickly stop acute bleeding and provide longer-term management of the condition.

Use in Postpartum Women

The use of Medroxyprogesterone Acetate in postpartum women is an area of ongoing research. Some studies have investigated the timing of DMPA administration after childbirth and its effects on breastfeeding, contraceptive continuation, and postpartum depression[6]. Key points include:

  • DMPA can be given to women after delivery for contraception.
  • The timing of administration (before hospital discharge or 4-6 weeks after delivery) may affect breastfeeding duration and exclusivity.
  • Researchers are studying its impact on rates of postpartum depression and use of highly effective contraception methods.

Potential Benefits for Sickle Cell Disease

Recent research is exploring the potential benefits of Medroxyprogesterone Acetate for women with sickle cell disease. A study is investigating whether DMPA can reduce the frequency and severity of pain episodes (known as vaso-occlusive episodes) in women with sickle cell disease[7]. This research aims to understand if hormonal contraception could have additional therapeutic benefits for this specific patient population.

Side Effects and Considerations

While Medroxyprogesterone Acetate is generally safe and effective, it can have side effects and considerations that patients should be aware of:

  • Irregular bleeding: Especially common in the first few months of use[4].
  • Potential impact on bone density: Long-term use may affect bone mineral density, although this is typically reversible after stopping the medication.
  • Weight changes: Some women may experience weight gain.
  • Delayed return to fertility: It may take several months for regular ovulation to resume after stopping DMPA.
  • Not suitable for everyone: Women with certain medical conditions or risk factors may not be able to use DMPA.

It’s important to discuss all potential benefits and risks with your healthcare provider to determine if Medroxyprogesterone Acetate is the right choice for you.

Aspect Details
Primary Uses Contraception, treatment of excessive vaginal bleeding
Administration Methods Intramuscular injection, subcutaneous injection, oral tablets
Typical Dosage 150 mg every 3 months (for contraception)
Areas of Research Self-administration, effects on breastfeeding, postpartum use, treatment of dysfunctional uterine bleeding
Potential Side Effects Studied Irregular bleeding, impact on breastfeeding, postpartum depression
Special Populations Postpartum women, women with fertility issues

FAQ

  • What is Medroxyprogesterone Acetate used for? Medroxyprogesterone Acetate is primarily used as a contraceptive method. It's also being studied for its potential use in treating excessive vaginal bleeding and as part of fertility treatments.
  • How is Medroxyprogesterone Acetate typically administered? It's usually given as an injection, either intramuscularly (into the muscle) or subcutaneously (under the skin). The typical dose is 150 mg every 3 months for contraception.
  • Are there any studies on self-administration of Medroxyprogesterone Acetate? Yes, there's a clinical trial comparing self-administration versus clinic administration of subcutaneous Depo-Provera to see if it affects continuation rates and user satisfaction.
  • Can Medroxyprogesterone Acetate affect breastfeeding? There's ongoing research to determine if the timing of Medroxyprogesterone Acetate administration after childbirth affects breastfeeding duration or exclusivity.
  • Are there any potential side effects of Medroxyprogesterone Acetate being studied? Yes, studies are looking at potential side effects such as irregular bleeding, especially during the first 90 days of use. Some research is also examining its potential impact on postpartum depression.

Ongoing Clinical Trials on Medroxyprogesterone Acetate

  • Study of MK-5684 compared to standard therapy in patients with breast cancer, ovarian cancer, or endometrial cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Tirzepatide for Women with Overweight or Obesity and Polycystic Ovary Syndrome (PCOS)

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study Comparing Medroxyprogesterone Acetate and Ganirelix for Women Undergoing Fertility Treatment with Embryo Accumulation

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Depot medroxyprogesterone acetate (DMPA): A long-acting reversible hormonal contraceptive injection containing the hormone progestin, typically given every 3 months.
  • Subcutaneous (SC): An injection that is given just under the skin, rather than into a muscle or vein.
  • Intramuscular (IM): An injection that is given directly into a muscle.
  • Bioequivalence: The property of two drug products having the same biological effect in the body.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Continuation rate: The percentage of people who continue to use a particular method of contraception over time.
  • Ovulation induction: A process of using medications to stimulate the ovaries to produce and release eggs.
  • Postpartum: The period of time immediately after childbirth.
  • Lactational amenorrhea: The natural postpartum infertility that occurs when a woman is breastfeeding.
  • Edinburgh Postnatal Depression Scale (EPDS): A screening tool used to identify women who may be at risk for postpartum depression.

References

  1. https://clinicaltrials.gov/study/NCT01019369
  2. https://clinicaltrials.gov/study/NCT00830414
  3. https://clinicaltrials.gov/study/NCT01143207
  4. https://clinicaltrials.gov/study/NCT00563576
  5. https://clinicaltrials.gov/study/NCT01148420
  6. https://clinicaltrials.gov/study/NCT01463202
  7. https://clinicaltrials.gov/study/NCT06665997